THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **HighTide Therapeutics, Inc.**, you should at once hand this circular with the enclosed form of proxy to the purchaser or transferee or to the bank, licensed securities dealer, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

HighTide Therapeutics, Inc.
君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
(2) PROPOSED RE-APPOINTMENT OF AUDITOR;
(3) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES;
AND
(4) NOTICE OF ANNUAL GENERAL MEETING

A notice convening the Annual General Meeting of HighTide Therapeutics, Inc. to be held at meeting room 24, 2/F, Building 10W, 10 Science Park West Avenue, Hong Kong Science Park, New Territories, Hong Kong on Monday, June 29, 2026 at 10:00 a.m. is set out on pages 22 to 27 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.hightidetx.com).

Whether or not you are able to attend the Annual General Meeting, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Hong Kong branch share registrar and transfer office of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the Annual General Meeting (i.e. by no later than 10:00 a.m. on Saturday, June 27, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude Shareholders from attending and voting at the Annual General Meeting or any adjournment thereof if they so wish.

June 2, 2026

CONTENTS

Page

DEFINITIONS 1

LETTER FROM THE BOARD 5

APPENDIX I – DETAILS OF RETIRING DIRECTORS PROPOSED FOR RE-ELECTION 12

APPENDIX II – EXPLANATORY STATEMENT 18

NOTICE OF ANNUAL GENERAL MEETING 22

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"2020 ESOP Platform"	Wisdom Spring Group Limited
"2020 Share Incentive Plan"	the employee long term incentive plan originally adopted by the Company on January 22, 2020, amended and restated on October 18, 2021 and further amended and restated in its entirety on March 4, 2022
"2023 ESOP Platform"	Wisdom Summer Group Limited
"2023 Share Incentive Plan"	the employee long term incentive plan adopted by the Company on May 24, 2023
"Annual General Meeting" or "AGM"	the annual general meeting of the Company to be held at meeting room 24, 2/F, Building 10W, 10 Science Park West Avenue, Hong Kong Science Park, New Territories, Hong Kong on Monday, June 29, 2026 at 10:00 a.m. or any adjournment thereof, the notice of which is set out on pages 22 to 27 of this circular
"Articles of Association" or "Articles"	the amended and restated articles of association of the Company conditionally adopted on December 11, 2023, and with effect from the Listing Date, as amended from time to time
"Board" or "Board of Directors"	the board of Directors of the Company
"Cayman Companies Act"	the Companies Act, Cap. 22 (As Revised) of the Cayman Islands
"CCASS"	Central Clearing and Settlement System
"China" or "PRC"	People's Republic of China, but for the purpose of this circular and for geographical reference only and except where the context requires otherwise, references in this circular to "China" and the "PRC" do not apply to Hong Kong, Macau and Taiwan
"close associate(s)"	has the meaning ascribed thereto under the Listing Rules
"Company"	HighTide Therapeutics, Inc., a company incorporated under the laws of the Cayman Islands with limited liability on February 28, 2018

"controlling shareholder(s)"	has the meaning ascribed thereto under the Listing Rules
"core connected person(s)"	has the meaning ascribed thereto under the Listing Rules
"Director(s)"	the director(s) of the Company
"Extension Mandate"	a general and unconditional mandate proposed to be granted to the Directors to the effect that any Shares repurchased under the Repurchase Mandate will be added to the total number of Shares under the Issue and Resell Mandate
"Group"	the Company and all of its subsidiaries or, where the context so requires, in respect of the period before the Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)
"Hepalink"	Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (深圳市海普瑞藥業集團股份有限公司), a joint stock limited company incorporated under the laws of the PRC, whose A shares are listed on the Shenzhen Stock Exchange (stock code: 002399) and H Shares are listed on the Stock Exchange (stock code: 9989)
"HK$"	Hong Kong Dollars, the lawful currency of Hong Kong
"HKSCC"	Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Issue and Resell Mandate"	a general and unconditional mandate proposed to be granted to the Directors at the Annual General Meeting to allot, issue and/or deal with the Shares (including the sale or transfer of treasury shares out of treasury) not exceeding 20% of the aggregate number of the shares of the Company in issue (excluding treasury shares) as at the date of passing of the relevant resolution granting the relevant mandate

"Latest Practicable Date"	May 29, 2026, being the latest practicable date prior to the publication of this circular for the purpose of ascertaining certain information contained in this circular
"Listing"	the listing of the Shares on the Main Board
"Listing Date"	December 22, 2023, the date on which dealings in the Shares first commenced on the Main Board
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Nomination Committee"	the nomination committee of the Board
"Repurchase Mandate"	a general and unconditional mandate proposed to be granted to the Directors at the Annual General Meeting to repurchase Shares not exceeding 10% of the aggregate number of the shares of the Company in issue (excluding the treasury shares) as at the date of passing of the relevant resolution granting the relevant mandate
"RMB"	the lawful currency of the PRC
"SFC"	the Securities and Futures Commission of Hong Kong
"SFO"	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
"Share(s)"	ordinary shares in the share capital of the Company with a par value of US$0.0001 each
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited

"subsidiary(ies)"	has the meaning ascribed thereto in Section 15 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong)
"substantial shareholder(s)"	has the meaning ascribed thereto under the Listing Rules
"Takeovers Code"	the Code on Takeovers and Mergers and Share Buy-backs issued by the SFC, as amended, supplemented or otherwise modified from time to time
"treasury shares"	has the meaning ascribed thereto under the Listing Rules as amended from time to time
"United States"	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"US$"	United States dollars, the lawful currency of the United States
"%"	per cent

HighTide Therapeutics, Inc.
君圣泰医药

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2511)

Executive Directors:
Dr. LIU Liping
(Chairwoman of the Board and chief executive officer)
Ms. YU Meng

Non-executive Directors:
Dr. ZHU Xun
Mr. MA Lixiong
(Deputy Chairman of the Board)
Mr. JIANG Feng

Independent Non-executive Directors:
Dr. LI Jin
Mr. HUNG Tak Wai
Mr. CHEN Mingyu

Registered office:
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

Principal place of business in Hong Kong:
40/F, Dah Sing Financial Centre
No. 248 Queen's Road East
Wan Chai
Hong Kong

June 2, 2026

To the Shareholders

Dear Sir or Madam

(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; AND (4) NOTICE OF ANNUAL GENERAL MEETING

I. INTRODUCTION

The purpose of this circular is to provide you with the notice of Annual General Meeting and further information regarding the following proposals to be put forward at the Annual General Meeting: (i) the re-election of the retiring Directors; (ii) the re-appointment of the auditor; (iii) the granting to the Directors of the Issue and Resell Mandate, the Repurchase Mandate and the Extension Mandate; and to give the Shareholders notice of the Annual General Meeting at which ordinary resolutions as set out in the notice of Annual General Meeting will be proposed.

II. MATTERS TO BE RESOLVED AT THE AGM

1. Proposed Re-Election of Retiring Directors

Pursuant to Article 84(1) of the Articles of Association, at each annual general meeting one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. Pursuant to Article 84(2) of the Articles of Association, a retiring Director shall be eligible for re-election, and any Director appointed by the Board pursuant to Article 83(3) of the Articles of Association shall not be taken into account in determining which particular Directors or the number of Directors who are to retire by rotation.

In accordance with Article 84 of the Articles of Association, Dr. LIU Liping, Mr. MA Lixiong, Mr. HUNG Tak Wai and Mr. CHEN Mingyu shall retire from their offices as Directors at the Annual General Meeting and, being eligible, will offer themselves for re-election at the Annual General Meeting.

Recommendation of the Nomination Committee

Having reviewed the Board's structure, size and composition, the respective qualifications, skills and experience, time commitment and contribution of each of Dr. LIU Liping, Mr. MA Lixiong, Mr. HUNG Tak Wai and Mr. CHEN Mingyu with reference to the nomination policy and the board diversity policy of the Company, the Nomination Committee has recommended to the Board the re-election as Directors of each of Dr. LIU Liping, Mr. MA Lixiong, Mr. HUNG Tak Wai and Mr. CHEN Mingyu, who are due to retire at the Annual General Meeting. Mr. HUNG Tak Wai and Mr. CHEN Mingyu, the retiring independent non-executive Directors, have confirmed their independence with reference to the factors set out in Rule 3.13 of the Listing Rules. The Nomination Committee considered that Mr. HUNG Tak Wai and Mr. CHEN Mingyu are independent in accordance with the independence guidelines set out in the Listing Rules; and were satisfied with all the retiring Directors' contribution (including Mr. HUNG Tak Wai's and Mr. CHEN Mingyu's) to the Company and that they will continue to bring valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning and diversity. The Nomination Committee therefore recommended the re-election of all the retiring Directors who are due to retire at the AGM.

Recommendation of the Board

Taking into consideration the recommendations of the Nomination Committee, the nomination policy, the board diversity policy of the Company and the independence confirmations from Mr. HUNG Tak Wai and Mr. CHEN Mingyu, the Board is of the view that Mr. HUNG Tak Wai and Mr. CHEN Mingyu will continue to bring broader views, valuable insights and professionalism to the Board whilst having sufficient diversity for the Board to discharge its functions effectively. Accordingly, the Board considers the re-election of each of Mr. HUNG Tak Wai and Mr. CHEN Mingyu to be in the best interests of the Company and the Shareholders as a whole.

At the Annual General Meeting, ordinary resolutions will be proposed to re-elect Dr. LIU Liping as an executive Director, Mr. MA Lixiong as a non-executive Director and Mr. HUNG Tak Wai and Mr. CHEN Mingyu as independent non-executive Directors.

Details of the above retiring Directors who are subject to re-election at the Annual General Meeting are set out in Appendix I to this circular in accordance with the relevant requirements of the Listing Rules.

2. Proposed Re-appointment of the Auditor

Pursuant to Rule 13.88 of the Listing Rules, an ordinary resolution will be proposed to re-appoint Moore CPA Limited ("**Moore**") as the auditor of the Company and to hold office until the conclusion of the next annual general meeting of the Company, to provide annual financial report audit services or other related consultancy services for the year ending December 31, 2026, and to authorize the Board to fix their remuneration.

The appointment of the auditor of the Company has been reviewed by the audit committee of the Board which made recommendation to the Board that the appointment be submitted and proposed for Shareholders' approval at the AGM. The estimated audit fee for the audit of the consolidated financial statements of the Group for the financial year ending December 31, 2026 is expected to range from approximately RMB1.45 million to RMB1.60 million. The estimated audit fee represents a fair and reasonable estimation, after due consideration and fair and reasonable negotiations between the Company and Moore. The estimation takes into account various factors such as the size and structure of the Group, the scale and complexity of the Group's businesses, the expected scope and timing of the audit work, the audit resources and level of effort required, the auditor's qualifications and experience, and the prevailing market rates for similar services. Furthermore, the estimated audit fee assumes there will be no material changes in the Group's businesses and operations, accounting policies or regulatory environment, and that the Company will provide timely and adequate assistance and information as required for the audit. As Moore is relatively familiar with the Group's financials and affairs, the Board considers that the audit and other related work in respect of the Group for the year ending December 31, 2026 could be performed more efficiently by Moore, which is in the best interests of the Company and the Shareholders as a whole.

Accordingly, Moore will retire as the auditor of the Company at the Annual General Meeting and, being eligible, offer themselves for re-appointment.

3. Proposed Granting of General Mandate to Issue and Resell Treasury Shares

In order to ensure flexibility and give discretion to the Directors, in the event that it becomes desirable for the Company to issue any new Shares (including the sale or transfer of treasury shares out of treasury), approval is to be sought from the Shareholders for the general mandate to issue Shares (including the sale or transfer of treasury shares out of treasury). At the Annual General Meeting, an ordinary resolution no. 4(A) will be proposed to grant the Issue and Resell Mandate to the Directors to exercise the powers of the Company to allot, issue and

deal with the additional Shares (including the sale or transfer of treasury shares out of treasury) in the share capital of the Company of up to 20% of the aggregate number of the Shares in issue (excluding treasury shares) as at the date of passing of the resolution in relation to the Issue and Resell Mandate.

As at the Latest Practicable Date, the issued share capital of the Company comprised 571,325,668 Shares and the Company did not hold any treasury shares. Subject to the passing of the ordinary resolution no. 4(A) and on the basis that no further Shares are issued or repurchased after the Latest Practicable Date and up to the Annual General Meeting, the Company will be allowed to issue (or sell or transfer out of treasury) a maximum of 114,265,133 Shares under the Issue and Resell Mandate, representing 20% of the aggregate number of the Shares in issue.

The Issue and Resell Mandate will continue to be in force from the passing of the said resolution until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the applicable laws or the Articles of Association; or (iii) the revocation or variation of the authority given under the resolution by an ordinary resolution of the Shareholders in general meeting.

4. Proposed Granting of General Mandate to Repurchase Shares

In addition, in order to give the Company the flexibility to repurchase Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Repurchase Mandate to the Directors to exercise the powers of the Company to repurchase the Shares representing up to 10% of the aggregate number of the Shares in issue (excluding treasury shares) as at the date of passing of the resolution in relation to the Repurchase Mandate.

As at the Latest Practicable Date, the issued share capital of the Company comprised 571,325,668 Shares and the Company did not hold any treasury shares. Subject to the passing of the ordinary resolution no. 4(B) and on the basis that no further Shares are issued or repurchased after the Latest Practicable Date and up to the Annual General Meeting, the Company will be allowed to buy back a maximum of 57,132,566 Shares under the Repurchase Mandate, representing 10% of the aggregate number of the Shares in issue.

The Repurchase Mandate, if approved, will continue to be in force until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under any applicable laws or the Articles of Association; or (iii) the revocation or variation of the authority given under the resolution by an ordinary resolution of the Shareholders in general meeting.

The Company has no current intention of exercising the Repurchase Mandate.

An explanatory statement required by the Listing Rules to be sent to the Shareholders in connection with the proposed Repurchase Mandate is set out in Appendix II to this circular. This explanatory statement contains all information reasonably necessary to enable the Shareholders to make an informed decision on whether to vote for or against the relevant resolution at the Annual General Meeting.

5. Proposed Granting of Extension Mandate

Subject to a separate approval of the ordinary resolution no. 4(C), the number of Shares repurchased by the Company under ordinary resolution no. 4(B) will also be added to extend the 20% limit of the Issue and Resell Mandate as mentioned in the ordinary resolution no. 4(A), provided that such additional amount shall not exceed 10% of the aggregate number of the Shares in issue (excluding treasury shares) as at the date of passing the resolutions in relation to the Issue and Resell Mandate and the Repurchase Mandate.

III. CLOSURE OF REGISTER OF MEMBERS

The transfer books and register of members of the Company will be closed from Wednesday, June 24, 2026 to Monday, June 29, 2026, both days inclusive, and Monday, June 29, 2026 be set as the record date, during which period no share transfers can be registered.

In order to be eligible for attending and voting at the Annual General Meeting, all transfers accompanied by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong not later than 4:30 p.m. on Tuesday, June 23, 2026 or any adjournment thereof (as the case may be).

IV. NOTICE OF ANNUAL GENERAL MEETING

Set out on pages 22 to 27 of this circular is the notice of the Annual General Meeting containing, *inter alia*, ordinary resolutions in relation to granting the Directors the Issue and Resell Mandate, the Repurchase Mandate and the Extension Mandate, as well as approving the re-election of the retiring Directors and the proposed re-appointment of auditor.

V. FORM OF PROXY

A form of proxy is enclosed for use at the Annual General Meeting. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.hightidetx.com). Whether or not you intend to be present at the Annual General Meeting, please complete the form of proxy in accordance with the instructions printed thereon and return it to the Hong Kong branch share registrar and transfer office of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, not less than 48 hours before the time fixed for the holding of the Annual General Meeting (i.e. by no later than 10:00 a.m. on Saturday, June 27,

2026) or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude Shareholders from attending and voting at the Annual General Meeting or any adjourned meeting thereof if they so wish and in such event, the form of proxy shall be deemed to be revoked.

VI. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting (save for certain procedural or administrative matters) must be taken by poll. The chairman of the Annual General Meeting shall therefore demand voting on all resolutions set out in the notice of Annual General Meeting be taken by way of poll pursuant to Article 66(1) of the Articles of Association. In addition, holders of treasury shares (if any) shall abstain from voting on matters that require shareholders' approval at the Company's general meetings.

VII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters or other material facts not contained in this circular, which, if omitted, would make any statement in this circular misleading.

VIII. RECOMMENDATION

The Board considers that the proposed resolutions in relation to granting the Directors the Issue and Resell Mandate, the Repurchase Mandate and the Extension Mandate, as well as approving the re-election of the retiring Directors and the proposed re-appointment of auditor, are fair and reasonable and are in the interests of the Company and the Shareholders as a whole. The Board therefore recommends the Shareholders to vote in favour of all the resolutions to be proposed at the Annual General Meeting.

Except for (i) Dr. LIU Liping's control by way of power of attorney over the unvested Shares under the 2020 ESOP Platform; and (ii) unvested Shares held by the 2023 ESOP Platform, which shall abstain from voting on matters that require Shareholders' approval under Rule 17.05A of the Listing Rules, no other Shareholder is required to abstain from voting in respect of any of the resolutions to be proposed at the Annual General Meeting.

IX. GENERAL INFORMATION

Your attention is drawn to the additional information set out in the Appendices to this circular. The English text of this circular shall prevail over the Chinese text.

Yours faithfully
By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

The following are the biographical details of the Directors (as required by the Listing Rules) proposed to be re-elected at the Annual General Meeting.

1. EXECUTIVE DIRECTOR

Dr. LIU Liping (劉利平), aged 56, founder of the Group, was appointed as a Director on February 28, 2018 and redesignated as an executive Director on May 15, 2023. Dr. Liu was appointed as the chairwoman of the Board upon Listing. Dr. Liu is primarily responsible for overall management of the business strategy, corporate development and research and development of the Group.

In addition to the Company, Dr. Liu has served the following positions in the Group:

- a director (and an executive director since October 2020) and chief executive officer of Shenzhen HighTide Biopharmaceutical Ltd. (深圳君聖泰生物技術有限公司) ("**Shenzhen HighTide**"), a wholly-owned subsidiary of the Company, since November 2011;

- a director of Shanghai HighTide Biopharmaceutical Ltd. (上海君聖泰生物技術有限公司), a wholly-owned subsidiary of the Company, from March 2014 to October 2020, and an executive director and chief executive officer thereof since October 2020;

- a director (and an executive director since October 2020) of JSK Consumer Healthcare, Ltd. (深圳君聖康生物技術有限公司), a wholly-owned subsidiary of the Company, since July 2015, and the chief executive officer thereof from July 2015 to March 2025;

- an executive director and the chief executive officer of HIGHTIDE BIOPHARMA PTY. LTD., a wholly-owned subsidiary of the Company, since August 2015;

- an executive director and the chief executive officer of HighTide Therapeutics, Ltd., a wholly-owned subsidiary of the Company, since March 2018;

- an executive director and the chief executive officer of HighTide Therapeutics USA, LLC, a wholly-owned subsidiary of the Company, since November 2019;

- an executive director and the chief executive officer of HighTide Therapeutics (Hong Kong) Limited, a wholly-owned subsidiary of the Company, since April 2018;

- an executive director since May 2021 of Shanghai Fusion Therapeutics, Ltd. (上海福藥生物技術有限公司), a wholly-owned subsidiary of the Company, and the chief executive officer thereof from May 2021 to March 2025;

- an executive director of Nanchang Fusion Therapeutics, Ltd. (南昌福藥生物技術有限公司), a wholly-owned subsidiary of the Company, since November 2021, and the chief executive officer thereof from November 2021 to March 2025; and

- an executive director of Hebei Puhui Pharmaceutical Co., Ltd. (河北普惠醫藥有限公司), a wholly-owned subsidiary of the Company since September 2023.

Dr. Liu has over 22 years of experience in the R&D of new drugs. Prior to founding the Group, Dr. Liu worked as a postdoctoral researcher in the Hospital for Sick Children in Canada from March 1995 to April 2000. From April 2000 to December 2002, she served as a director of antigen discovery of CTL ImmunoTherapies Corporation. From January 2003 to September 2005, she served as a group leader in chemistry department of MannKind Corporation. From September 2005 to May 2008, Dr. Liu worked in the translational research department of American Type Culture Collection where she was primarily responsible for biomarker discovery, translational research and drug discovery. Dr. Liu served as a senior director of R&D of Stealth Peptide Inc. from May 2008 to August 2010. From February 2011 to April 2011, she served as the managing director of ABLE BioGroup LLC. On November 15, 2011, Dr. Liu established Shenzhen HighTide together with Hepalink.

Dr. Liu obtained her bachelor's degree in chemistry and doctoral degree in physics of polymers from Nankai University (南開大學) in the PRC in July 1990 and December 1994, respectively. Dr. Liu obtained a master of business administration from Johns Hopkins University Carey Business School in May 2009 in the United States. Dr. Liu was awarded Technology Innovation and Entrepreneurial Talent by the Ministry of Science and Technology of the PRC in March 2014 and Distinguished Expert in Longgang District by the People's Government of Longgang District, Shenzhen in November 2017. She was also regarded as Top 10 Drug Innovative Scientist by Securities Times in May 2021. Dr. Liu was awarded the EY Entrepreneurial Winning Women Asia-Pacific in 2023.

Dr. Liu has entered into a service contract with the Company, under which the initial term of her service contract shall commence from the Listing Date and continue for a period of three years after or until the third annual general meeting of the Company since the Listing Date, whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the Articles), until terminated in accordance with the terms and conditions of the service contract or by either party giving to the other not less than three months' prior notice in writing. Pursuant to the service contract entered into with the Company, Dr. Liu is not entitled to any remuneration as director's fee.

As at the Latest Practicable Date, Dr. Liu was interested in 117,095,740 Shares within the meaning of Part XV of the SFO including (i) 81,000,000 Shares held by the GREAT Mantra Group Limited, (ii) 10,004,964 Shares underlying awards that were granted to Dr. Liu under the 2020 Share Incentive Plan and (iii) 26,090,776 Shares attached to which Dr. Liu was entitled to the voting rights pursuant to the voting agreements entered into by the Company and certain grantees under the 2020 Share Incentive Plan, representing 20.50% of the issued share

capital of the Company in aggregate. Save as disclosed above, as far as the Directors are aware, as at the Latest Practicable Date, Dr. Liu was not interested or deemed to be interested in any Shares or underlying Shares of the Company or its associated corporations pursuant to Part XV of the SFO.

2. NON-EXECUTIVE DIRECTOR

Mr. MA Lixiong (馬立雄), aged 51, joined the Group and was appointed as a Director on November 16, 2021 and was re-designated as a non-executive Director on May 15, 2023. Mr. Ma is primarily responsible for providing guidance and advice on the corporate and business strategies of the Group. Mr. Ma mainly holds the current directorship and management positions in the following companies:

- an executive director and general manager in Yuthai Investment Management Co., Ltd. (昱烽晟泰投資管理有限公司) since April 2015;
- an executive director and general manager in Shenzhen AIH Capital Management Co., Ltd. (深圳市德正嘉成投資管理有限公司) since October 2015; and
- a director in Qide Technology Group Ltd. (啟德科技集團有限公司) since February 2021.

Mr. Ma served as a senior auditor at the PWC from 1998 to 2003. He served as a vice president at the Hong Kong First Investment Group Limited from 2004 to 2015.

Mr. Ma obtained his bachelor's degree in international accounting from Shenzhen University (深圳大學) in June 1998 in the PRC. He obtained the professional qualification in fund in December 2016.

Mr. Ma has entered into an appointment letter with the Company, under which the initial term of his appointment letter shall commence from the Listing Date and continue for a period of three years after or until the third annual general meeting of the Company since the Listing Date, whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the Articles), until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing. Pursuant to the appointment letter entered into with the Company dated April 1, 2025, Mr. Ma is entitled to receive an annual remuneration of HK$600,000 as director's fee.

As at the Latest Practicable Date, Mr. Ma was interested in 34,320,738 Shares within the meaning of Part XV of the SFO including (i) 27,428,154 Shares held by BAIYI Capital Limited, (ii) 2,766,000 Shares held by Pingtan Rongjing Investment Partnership (Limited Partnership) (平潭榮景投資合夥企業(有限合夥)), and (iii) 4,126,584 Shares underlying awards that were granted to Mr. Ma under the 2020 Share Incentive Plan and 2023 Share Incentive

Plan, representing 6.01% of the issued share capital of the Company in aggregate. Save as disclosed above, as far as the Directors are aware, as at the Latest Practicable Date, Mr. Ma was not interested or deemed to be interested in any Shares or underlying Shares of the Company or its associated corporations pursuant to Part XV of the SFO.

3. INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. HUNG Tak Wai (孔德偉), aged 67, was appointed as an independent non-executive Director with effect from the Listing. He is responsible for supervising and providing independent recommendations to the Board.

Mr. Hung worked at UBS AG, Hong Kong from October 2001 to March 2009. Mr. Hung was the project director in the equity & derivatives department of BNP Paribas Hong Kong Branch from November 2009 to August 2011, a managing director in UBS Corporate Management (Shanghai) Co. Ltd. from October 2011 to September 2012, an assistant president in China Merchant Securities Co. Limited from November 2012 to October 2018, a senior adviser in Macquarie Capital Limited from June 2019 to June 2020 and a senior adviser in Expecta Capital Limited since May 2022.

Mr. Hung obtained the senior management qualification for securities companies issued by the CSRC in June 2007. He was a vice-chair of the Asset Securitization and Structured Financing Professional Committee (資產證券化暨結構化融資專業委員會委員) in National Association of Financial Market Institutional Investors (中國銀行間市場交易商協會) from April 2018 to September 2022.

Mr. Hung obtained his bachelor degree of science in industrial chemistry in the City University in London in June 1981 and his master degree of science in chemical engineering in Columbia University in the USA in January 1983.

Mr. Hung has entered into an appointment letter with the Company, under which the initial term of his appointment letter shall commence from the Listing Date and continue for a period of three years after or until the third annual general meeting of the Company since the Listing Date, whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the Articles), until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing. Pursuant to the appointment letter entered into with the Company, Mr. Hung will receive an annual remuneration of HK$200,000 as director's fee.

As at the Latest Practicable Date, Mr. Hung was not interested or deemed to be interested in any Shares or underlying Shares of the Company or its associated corporations within the meaning of Part XV of the SFO.

Mr. Hung confirmed that he meets the independence criteria set out in Rule 3.13 of the Listing Rules. Mr. Hung also confirmed that he has no past or present financial or other interest in the business of the Company or its subsidiaries and has no connection with any core connected person (as defined in the Listing Rules) of the Company, and that there are no other factors that may affect his independence.

Mr. CHEN Mingyu (陳明宇), aged 63, is currently the managing partner of D&E (Beijing) Business Consulting Co., Ltd., a finance, tax and business advisory service firm since 2019 and a visiting professor in the Executive Masters in Business Administration program at Tsinghua University since 2018. Mr. Chen has over 35 years of international experience in finance and taxation, including extensive hands-on involvement in financial reporting oversight, audit committee leadership, internal control evaluation, and risk management. His business expertise particularly focuses on providing financial and tax advisory services to Chinese enterprises expanding globally and operating overseas. His professional areas cover guiding cross-border merger and acquisition transactions, corporate valuation, personal wealth management, and designing and implementing global holding company structures for Chinese multinational companies, which combine tax optimization, financing, and capital repatriation strategies. From 1995 to 2018, Mr. Chen consecutively served as a partner in tax and business advisory at three leading global accounting firms: Deloitte, Ernst & Young, and KPMG, where he worked closely with audit teams on financial due diligence, reviewed the tax implications of complex financial statements, participated in assessing internal control frameworks for multinational clients, and gained practical experience in reviewing audit procedures related to cross-border transactions and evaluating compliance with applicable financial reporting standards (e.g., IFRS and HKFRS).

Mr. Chen currently serves as the chairman of the audit committee and an independent non-executive director of Yadea Group Holdings Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 1585) since June 16, 2023. He has also served as an independent non-executive director of China National Medicines Corporation Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600511) since April 7, 2022; G.H.Y Culture & Media Holding Co., Limited (a company listed on the Singapore Stock Exchange, stock code: XJB) since November 23, 2020; and Fujian Cosunter Pharmaceutical Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300436) from January 6, 2021 to June 24, 2024.

Mr. Chen holds a Master of Business Administration from Fordham University in the United States, and has been a certified Chinese Tax Agent since 2000.

Mr. Chen has entered into an appointment letter with the Company, under which the initial term of his appointment letter shall commence from May 4, 2026 and continue for a period of three years or until the third annual general meeting of the Company since the date of appointment, whichever is earlier, and shall be automatically renewed for successive periods of three years (subject always to re-election as and when required under the memorandum and articles of association of the Company) until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than one months' prior notice in writing. Pursuant to the appointment letter entered into with the Company, Mr. Chen will receive an annual remuneration of HK$200,000 as director's fee.

As at the Latest Practicable Date, Mr. Chen was not interested or deemed to be interested in any Shares or underlying Shares of the Company or its associated corporations within the meaning of Part XV of the SFO.

Mr. Chen confirmed that he meets the independence criteria set out in Rule 3.13 of the Listing Rules. Mr. Chen also confirmed that he has no past or present financial or other interest in the business of the Company or its subsidiaries and has no connection with any core connected person (as defined in the Listing Rules) of the Company, and that there are no other factors that may affect his independence.

4. OTHER INFORMATION

Save as disclosed above, none of the Directors has or is proposed to have entered into any service agreement or letter of appointment with any member of the Group (excluding agreements expiring or determinable by any member of the Group within one year without payment of compensation other than statutory compensation).

Save as disclosed in this circular, to the best knowledge of the Company, each of the Directors who stands for re-election (i) has not held any directorships in other listed public companies in Hong Kong or overseas during the past three years; (ii) does not hold any other position with the Company and its subsidiaries; and (iii) does not have any other relationship with any of the other Directors, senior management of the Company, substantial shareholders or controlling shareholders of the Company.

In addition, save as disclosed in this circular, as far as the Directors are aware, there is no other matter concerning each of the aforementioned retiring Directors that needs to be brought to the attention of the Shareholders, and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The following is the explanatory statement required by the Stock Exchange to be sent to the Shareholders under the Listing Rules in connection with the proposed Repurchase Mandate.

1. LISTING RULES

The Listing Rules permit a company whose primary listing is on the Stock Exchange to repurchase its shares on the Stock Exchange and any other stock exchange on which the securities of the company are listed and such exchange is recognized by the SFC and the Stock Exchange subject to certain restrictions. Among such restrictions, the Listing Rules provide that the shares of such company must be fully paid up and all repurchase of shares by such company must be approved in advance by an ordinary resolution of Shareholders, either by way of a general repurchase mandate or by specific approval of a particular transaction.

2. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 571,325,668 Shares of nominal value of US$0.0001 each. Subject to the passing of the resolution granting the Repurchase Mandate and on the basis that no further Shares are issued or repurchased after the Latest Practicable Date and up to the Annual General Meeting, the Company will be allowed to repurchase a maximum of 57,132,566 Shares, representing 10% of the aggregate number of the Shares in issue (excluding treasury shares) during the period ending on the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under any applicable laws or the Articles of Association; or (iii) the revocation or variation of the authority given under the resolution by an ordinary resolution of the Shareholders of the Company in general meeting.

3. STATUS OF REPURCHASED SHARES

The Shares repurchased by the Company may be held as treasury shares or may be cancelled subject to, among others, market conditions and its capital management needs at the relevant time of the repurchases, which may change due to evolving circumstances. The Shareholders and potential investors should pay attention to any announcement to be published by the Company in the future, including but without limitation, any next day disclosure return (which shall identify, amongst others, the number of repurchased Shares that are to be held in treasury or cancelled upon settlement of such repurchases) and relevant monthly return.

For any treasury shares of the Company deposited with CCASS pending resale on the Stock Exchange, the Company shall, upon approval by the Board implement the below interim measures which include (without limitation):

(i) procuring its broker not to give an instruction to HKSCC to vote at general meetings for the treasury shares deposited with CCASS;

(ii) in the case of dividends or distributions (if any and where applicable), withdrawing the treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case before the relevant record date for the dividend or distributions; or

(iii) taking any other measures to ensure that it will not exercise any Shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury shares.

The listing of all Shares which are purchased by the Company (whether on the Stock Exchange or otherwise) but not held as treasury shares shall be cancelled upon repurchase. The Company shall ensure that the documents of title of these repurchased Shares are cancelled and destroyed as soon as reasonably practicable following settlement of any such repurchase.

4. REASONS FOR AND FUNDING OF REPURCHASES

The Board believes that it is in the best interests of the Company and the Shareholders as a whole to seek a general authority from the Shareholders to enable the Company to repurchase its Shares. A repurchase of Shares may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net value of the Company and/or its earnings per Share and will only be made when the Board believes that such repurchase will be to the benefit of the Company and the Shareholders as a whole.

The Board proposes that the repurchase of Shares under the Repurchase Mandate would be financed from internal resources of the Company. It is envisaged that the funds required for any repurchase would be derived from the capital paid up on the Shares being repurchased and from the distributable profits of the Company, as well as any funds legally available for such purposes in accordance with the Company's Articles of Association, the Cayman Companies Act or other applicable laws of the Cayman Islands and the Listing Rules. The Cayman Companies Act provides that the amount of capital repaid in connection with a share repurchase may be paid out of the profits of the Company or the proceeds of a fresh issue of Shares made for the purposes of the repurchase or out of capital subject to and in accordance with the Cayman Companies Act. The amount of premium over the par value of the Shares payable on repurchase may only be paid out of either the profits of the Company or out of the share premium account before or at the time the Shares are repurchased in the manner provided for in the Cayman Companies Act.

5. MATERIAL ADVERSE IMPACT

The Directors currently have no intention to repurchase any Shares, and they would only exercise the power to repurchase Shares in circumstances where they consider that such repurchase would be in the best interests of the Company and the Shareholders as a whole. The Board is of the view that any repurchase of Shares (including the exercise of the Repurchase Mandate in full) would not have a material adverse impact on the working capital or gearing position of the Company, as compared with the positions disclosed in the audited consolidated

financial statements of the Company for the year ended December 31, 2025, being the date to which the latest published audited consolidated financial statements of the Company were made up. The Board does not propose to exercise the Repurchase Mandate to an extent which would, in the circumstances, have a material adverse effect on the working capital or gearing position of the Company.

6. TAKEOVERS CODE

If, as a result of a repurchase of the Shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert (within the meaning of the Takeovers Code), depending on the level of increase in the Shareholder or Shareholders' interest, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code. Save as aforesaid, the Directors are not aware of any consequences which may arise under the Takeovers Code if the Repurchase Mandate is exercised.

The Listing Rules prohibit a company from making a repurchase on the Stock Exchange if the result of the repurchase would be that less than 25% (or such other prescribed minimum percentage as determined by the Stock Exchange) of the issued share capital of the company would be held by the public. The Directors currently do not have any intention to repurchase Shares which would result in less than the prescribed minimum percentage of Shares being held by the public.

7. DIRECTORS, THEIR CLOSE ASSOCIATES AND THE COMPANY'S CORE CONNECTED PERSONS

None of the Directors nor, to the best of their knowledge having made reasonable enquiries, any of their close associates has any present intention, in the event that the Repurchase Mandate is approved by Shareholders, to sell Shares to the Company. No core connected person of the Company has notified the Company that he/she/it has any present intention to sell Shares to the Company, or has undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

8. UNDERTAKING

The Directors have undertaken to exercise the power of the Company to make repurchases pursuant to the proposed Repurchase Mandate in accordance with the Listing Rules, the Cayman Companies Act or other applicable laws of the Cayman Islands and the Articles of Association.

The Company confirms that neither the explanatory statement nor the Repurchase Mandate has unusual features.

9. SHARE REPURCHASE BY THE COMPANY

No repurchases of Shares (whether on the Stock Exchange or otherwise) were made by the Company during the six months prior to the Latest Practicable Date.

10. SHARE PRICES

The highest and lowest prices per Share at which the Shares have traded on the Stock Exchange during each of the previous 12 months prior to the Latest Practicable Date were as follows:

Month	**Highest price** *HK$*	**Lowest price** *HK$*
2025		
June	3.75	1.88
July	3.92	2.62
August	3.58	2.99
September	4.70	3.20
October	4.20	3.28
November	3.88	2.54
December	3.30	2.52
2026		
January	3.10	2.55
February	2.79	2.28
March	3.50	1.80
April	4.08	2.97
May (up to the Latest Practicable Date)	4.72	2.94

HighTide Therapeutics, Inc.
君圣泰医药

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2511)

NOTICE IS HEREBY GIVEN THAT the annual general meeting (the "**Annual General Meeting**") of HighTide Therapeutics, Inc. (the "**Company**") will be held at meeting room 24, 2/F, Building 10W, 10 Science Park West Avenue, Hong Kong Science Park, New Territories, Hong Kong on Monday, June 29, 2026 at 10:00 a.m. for the following purposes. Words and expressions that are not expressly defined in this notice of Annual General Meeting shall bear the same meanings as those defined in the circular of the Company dated June 2, 2026.

ORDINARY RESOLUTIONS

1. To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the "**Directors**") and auditor of the Company for the year ended December 31, 2025.

2. (A) To re-elect the following retiring Directors:

   (i) Dr. LIU Liping as an executive Director of the Company;

   (ii) Mr. MA Lixiong as a non-executive Director of the Company;

   (iii) Mr. HUNG Tak Wai as an independent non-executive Director of the Company; and

   (iv) Mr. CHEN Mingyu as an independent non-executive Director of the Company.

   (B) To authorize the board of Directors (the "**Board**") to fix the remuneration of the Directors.

3. To re-appoint Moore CPA Limited as auditor of the Company and authorize the Board to fix their remuneration.

4. To consider and, if thought fit, pass the following resolutions as ordinary resolutions:

(A) "**That**:

(i) subject to paragraph (iii) below, the exercise by the directors of the Company during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue or otherwise deal with additional shares in the capital of the Company (including any sale or transfer of treasury shares out of treasury) or securities convertible into shares, or options, warrants or similar rights to subscribe for shares or such convertible securities of the Company and to make or grant offers, agreements and/or options (including bonds, warrants and debentures convertible into shares of the Company) which may require the exercise of such powers be and is hereby generally and unconditionally approved;

(ii) the approval in paragraph (i) of this resolution above shall be in addition to any other authorisation given to the directors of the Company and shall authorise the directors of the Company during the Relevant Period (as hereinafter defined) to make or grant offers, agreements and/or options which may require the exercise of such power after the end of the Relevant Period;

(iii) the aggregate number of shares which may be allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) and treasury shares which may be sold or transferred or agreed conditionally of unconditionally to be sold or transferred by the directors of the Company during the Relevant Period (as hereinafter defined) pursuant to paragraph (i) of this resolution above, otherwise than pursuant to (1) a Rights Issue (as hereinafter defined); or (2) the grant or exercise of any option under the option scheme of the Company or any other option, scheme or similar arrangement for the time being adopted for the grant or issue to the directors, officers and/or employees of the Company and/or any of its subsidiaries of shares or rights to acquire shares of the Company; or (3) any scrip dividend or similar arrangement providing for the allotment of shares (and/or the sale or transfer of treasury shares) in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company in force from time to time; or (4) any issue of shares in the Company upon the exercise of rights of subscription or conversion under the terms of any existing convertible notes issued by the Company or any existing securities of the Company which carry rights to subscribe for or are convertible into shares of the Company, shall not exceed the aggregate of 20% of the aggregate number of the shares of the Company in issue (excluding treasury shares) as at the date of passing this resolution and the said approval shall be limited accordingly; and

(iv) for the purpose of this resolution:

(a) "**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(1) the conclusion of the next annual general meeting of the Company;

(2) the expiration of the period within which the next annual general meeting of the Company is required by any applicable laws or the articles of association of the Company to be held;

(3) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting; and

(b) "**Rights Issue**" means an offer of shares in the capital of the Company, or an offer or issue of warrants, options or other securities giving rights to subscribe for shares, open for a period fixed by the directors of the Company to holders of shares in the capital of the Company or any class thereof whose names appear on the register of members on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusion or other arrangements as the directors of the Company may deem necessary or expedient in relation to fractional entitlements or, having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the exercise or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, any recognised regulatory body or any stock exchange applicable to the Company)."

(B) "**That**:

(i) subject to paragraph (iii) below, the exercise by the directors of the Company during the Relevant Period (as hereinafter defined) of all the powers of the Company to repurchase shares of the Company on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") or on any other stock exchange on which the shares of the Company may be listed and recognised for this purpose by the Securities and Futures Commission and the Stock Exchange under the Code on Share Buy-backs and, subject to and in accordance with all applicable laws and the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), be and is hereby generally and unconditionally approved;

(ii) the approval in paragraph (i) of this resolution above shall be in addition to any other authorisation given to the directors of the Company and shall authorise the directors of the Company during the Relevant Period (as hereinafter defined) to procure the Company to repurchase its shares at a price determined by the Directors;

(iii) the aggregate number of the shares of the Company in issue, which may be repurchased by the Company during the Relevant Period (as hereinafter defined) pursuant to the approval in paragraph (i) above shall not exceed 10% of the aggregate number of the shares of the Company in issue (excluding treasury shares) as at the date of passing of this resolution, and the said approval shall be limited accordingly;

(iv) subject to the passing of each of the paragraphs (i), (ii) and (iii) of this resolution, any prior approvals of the kind referred to in paragraphs (i), (ii) and (iii) of this resolution which had been granted to the directors of the Company and which are still in effect be and are hereby revoked; and

(v) for the purpose of this resolution:

"**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(a) the conclusion of the next annual general meeting of the Company;

(b) the expiration of the period within which the next annual general meeting of the Company is required by any applicable laws or the articles of association of the Company to be held; and

(c) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting."

(C) "**That** conditional upon the resolutions numbered 4(A) and 4(B) set out in the notice convening this meeting being passed, the general mandate granted to the directors of the Company pursuant to the ordinary resolution numbered 4(A) set out in the notice convening this meeting be and is hereby extended by the addition to the aggregate number of the shares of the Company in issue of an amount representing the aggregate number of the shares of the Company in issue repurchased by the Company under the authority granted pursuant to ordinary resolution numbered 4(B) set out in the notice convening this meeting, provided that such extended amount shall not exceed 10% of the aggregate number of the shares of the Company in issue (excluding treasury shares) as at the date of passing of this resolution."

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, June 2, 2026

Registered office:
Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

Principal place of business in Hong Kong:
40/F, Dah Sing Financial Centre
No. 248 Queen's Road East
Wan Chai
Hong Kong

Notes:

(i) A shareholder entitled to attend and vote at the Annual General Meeting is entitled to appoint another person as his/her proxy to attend and vote instead of him/her; a proxy need not be a shareholder of the Company. A shareholder who is the holder of two or more shares may appoint more than one proxy to represent him/her and vote on his/her behalf at the Annual General Meeting. On a poll, votes may be given either personally or by proxy.

(ii) In the case of joint holders of any share(s), any one of such joint holders may attend or vote, whether in person or by proxy, in respect of such share(s) as if he/she/it was solely entitled thereto. If more than one of such joint holders are present at the Annual General Meeting, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.

(iii) In order to be valid, a form of proxy must be deposited at the Hong Kong branch share registrar and transfer office of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong together with the power of attorney or other authority (if any) under which it is signed (or a notarially certified copy thereof) not less than 48 hours before the time appointed for the holding of the above meeting (i.e. no later than 10:00 a.m. on Saturday, June 27, 2026) or any adjournment thereof. The completion and return of the form of proxy shall not preclude shareholders of the Company from attending and voting at the above meeting (or any adjourned meeting thereof) if they so wish.

(iv) The transfer books and register of members of the Company will be closed from Wednesday, June 24, 2026 to Monday, June 29, 2026, both days inclusive, and Monday, June 29, 2026 be set as the record date, during which period no share transfers can be registered. In order to be eligible for attending and voting at the Annual General Meeting, all transfers accompanied by the relevant share certificates must be lodged with the Hong Kong branch share registrar and transfer office of the Company, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong not later than 4:30 p.m. on Tuesday, June 23, 2026.

(v) In respect of ordinary resolutions numbered 2 above, Dr. LIU Liping, Mr. MA Lixiong and Mr. HUNG Tak Wai and Mr. CHEN Mingyu shall retire at the Annual General Meeting and being eligible, have offered themselves for re-election at the above meeting. Details of the above retiring directors of the Company are set out in Appendix I to the accompanied circular dated June 2, 2026.

(vi) Non-registered Shareholders whose Shares are held in the Central Clearing and Settlement System through banks, brokers, custodians or Hong Kong Securities Clearing Company Limited may also be able to attend and vote at the Annual General Meeting. In this regard, they should consult directly with their banks, brokers or custodians (as the case may be) for the necessary arrangements.

(vii) The Chinese translation of this notice is for reference only, and in case of any inconsistency, the English version shall prevail.

As at the date of this notice, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Dr. LI Jin, Mr. HUNG Tak Wai and Mr. CHEN Mingyu as independent non-executive Directors.